Advanced Infusion Systems - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The advanced infusion systems market size is projected to expand from USD 8.67 billion in 2025 and USD 9.38 billion in 2026 to USD 13.95 billion by 2031, registering a CAGR of 8.24% between 2026 to 2031. This report is Segmented by Product Type (Volumetric Infusion Systems, Syringe Infusion Systems, and More), by Application (Oncology and Chemotherapy, Diabetes Management, and More), by End User (Hospitals, Specialty Clinics, and More), by Technology (Smart Infusion Pumps and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Advanced Infusion Systems Market Trends and Insights

Rising Chronic Disease and Oncology Treatment Demand

Cancer created an estimated 20.6 million new cases and close to 10 million deaths annually, according to the World Health Organization’s 2026 report. The report expects annual new cases to approach 35 million by 2050 if current patterns continue. This growing treatment burden supports investment in infusion equipment, chemotherapy capacity, and specialty oncology services. Complex oncology regimens require controlled dosing, longer administration periods, and closer monitoring during treatment. These requirements favor advanced systems that can support high-acuity treatment protocols across hospital and community oncology settings. The Advanced Infusion Systems Market benefits as healthcare providers update equipment to support a larger and more complex patient population.

Migration to Home and Alternate-Site Infusion

Infusion therapy is moving from hospital departments to home and alternate-care locations. This change expands demand for ambulatory and elastomeric devices that are designed for use outside acute-care facilities. The Centers for Medicare & Medicaid Services published its CY 2026 national home infusion therapy rates on December 2, 2025. The rates reflected a 2.0% CPI-U productivity-adjusted increase and provide a reimbursement reference for providers planning Advanced Infusion Systems Market home infusion capacity. Home care requires different service models because clinicians need access to therapy information without relying on hospital documentation processes. The Advanced Infusion Systems Market is therefore shifting toward systems that combine mobility, straightforward operation, and remote access to treatment data.

High Fleet Replacement and Total Ownership Costs

The cost of replacing an infusion fleet extends beyond the device purchase price. Hospitals also need drug library licenses, connectivity infrastructure, software maintenance, cybersecurity controls, and staff training. These costs can delay upgrades at mid-size and community hospitals with limited capital budgets. Baxter reported lower infusion pump sales in its first-quarter 2026 results, partly because of a shipment and installation hold on Novum IQ LVP. The update shows that operational constraints can postpone revenue even after a product is ready for deployment. Health systems in emerging economies may continue to use lower-cost volumetric pumps, which limits Advanced Infusion Systems Market adoption because they cannot fund a full smart-pump ecosystem.

Other drivers and restraints analyzed in the detailed report include:

• EHR-Integrated Smart Pump Replacement Cycles
• Specialty Biologics and Precision-Dosing Requirements
• Cybersecurity, Recall, and Software-Liability Exposure

Segment Analysis

Volumetric infusion systems held 38.16% of the Advanced Infusion Systems revenue share in 2025. Their position reflects their role in acute care, intensive care, and oncology treatments that need precise, large-volume delivery. Syringe infusion systems remain important in perioperative care and neonatal intensive care, where small-volume delivery must be carefully controlled. Patient-controlled analgesia pumps continue to serve post-surgical pain management programs. Elastomeric systems are gaining use in home antibiotic therapy and ambulatory oncology because they are disposable and do not require electronic programming. Their simpler operating model can be useful in lower-acuity settings with limited technical support.

Ambulatory infusion systems are forecast to grow at a 9.76% CAGR through 2031, the highest rate among product types. Payers and health systems are directing selected IV therapies to outpatient and home settings. This movement changes product demand because ambulatory systems are designed for mobility and distributed care. ICU Medical introduced the Plum Solo and Plum Duo in April 2025 with FDA clearances for precision IV delivery. The devices combine blood product compatibility, EHR connectivity, and ±3% real-world dosing accuracy. These features narrow the gap between hospital-grade precision and systems used across adjacent treatment settings in the Advanced Infusion Systems Market.

Oncology and chemotherapy accounted for 31.77% of the Advanced Infusion Systems Market size in 2025. Multi-session treatment protocols create recurring demand for capital equipment and infusion disposables. Complex antibody-based and combination regimens are lengthening infusion sessions and increasing administration requirements. This establishes a demand base for infusion systems even as some subcutaneous alternatives become available. Pain management, parenteral nutrition, pediatrics, and neonatology continue to provide stable application demand. Gastroenterology also adds procedure volumes as infusion-based biologics are used in specialty care within the Advanced Infusion Systems Market.

Diabetes management is projected to grow at a 10.12% CAGR through 2031. Automated insulin delivery systems are changing insulin pumps into connected platforms that combine algorithms, sensors, and pumps. Medtronic announced Medicare access in February 2026 for the MiniMed 780G system with the Instinct sensor. The company also reported FDA clearance for use by people with insulin-requiring type 2 diabetes. This access expansion broadens use beyond type 1 diabetes and supports demand for closed-loop treatment systems. The Advanced Infusion Systems Market includes this fast-moving category because insulin delivery increasingly depends on device connectivity and automated dosing capabilities.

Complete Report Scope:

• By Product Type
  • Volumetric Infusion Systems
  • Syringe Infusion Systems
  • Ambulatory Infusion Systems
  • Elastomeric Infusion Systems
  • Patient-Controlled Analgesia Pumps
  • Others
• By Application
  • Oncology and Chemotherapy
  • Diabetes Management
  • Pain Management and Analgesia
  • Parenteral and Clinical Nutrition
  • Gastroenterology
  • Pediatrics and Neonatology
  • Others
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Home Care Settings
  • Others
• By Technology
  • Smart Infusion Pumps
  • Specialty Infusion Pumps
  • Wireless and Connected Infusion Pumps
  • AI-Enabled Infusion Platforms
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.44% of the Advanced Infusion Systems revenue share in 2025. The region benefits from a high concentration of EHR-integrated hospital networks and established reimbursement for hospital and home infusion therapy. CMS published updated CY 2026 home infusion therapy national rates in December 2025. The 2.0% CPI-U productivity-adjusted increase provides a reimbursement reference for home infusion providers. Canada contributes demand through provincial health systems, while Mexico is supported by private hospital development and a growing chronic disease burden. Hospitals that delayed purchases after the pandemic are now entering replacement cycles, which can increase competition for large contracts.

Europe is the second-largest regional segment in the Advanced Infusion Systems Market. Germany has high healthcare spending, broad use of precision dosing protocols, and a domestic manufacturing base that includes B. Braun and Fresenius Kabi. A German public procurement notice published in March 2026 covered a planned hospital-wide replacement of infusion and syringe pumps. The notice reflects ongoing equipment renewal among European hospitals. EU Medical Device Regulation compliance also encourages the replacement of systems that cannot meet current software and cybersecurity requirements. BD launched its neXus infusion and medication management platform in the United Kingdom and Ireland in May 2025, showing continued investment in the regional Advanced Infusion Systems Market installed base.

Asia-Pacific is forecast to expand at a 9.56% CAGR through 2031, making it the fastest-growing regional segment. China is increasing hospital capacity, and India is expanding private healthcare and community care delivery. These conditions support demand for ambulatory, cost-conscious, and connected infusion systems.

List of Companies Covered in this Report:

• Avanos Medical
• B. Braun
• Baxter
• Beckton Dickinson
• Caesarea Medical Electronics Ltd.
• Eitan Medical
• Fresenius
• ICU Medical
• InfuSystem Holdings, Inc.
• InfuTronix Solutions LLC
• Insulet
• JMS Co., Ltd.
• Medtronic
• Mindray
• Nipro
• Mindray
• Smiths Group
• Tandem Diabetes Care
• Terumo
• Zyno Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support